## **Clean Copy of Amended Paragraph**

## Page 1, Paragraph 1

Al

This application is a continuation of Application Serial No. 09/382,816, filed August 25, 1999, abandoned, which is a continuation of Application Serial No. 08/719,367, now U.S. Patent No. 6,022,730, filed September 25, 1996, which is a Continuation-In-Part of Application Serial No. 08/261,977, filed June 17, 1994, abandoned.

## **Clean Copy of Amended Claims**

11.(amended) The method according to claim 1, wherein said virally-infected cell is infected with a virus selected from the group consisting of the murine L-cell virus, simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), Ableson murine leukemia virus and Moloney murine leukemia virus.

12. (amended) The method according to claim 11, wherein said virus is the murine L-cell virus.

19. (amended) The method according to claim 15, wherein said virally-infected eukaryotic cell is a human brain capillary endothelial cell infected with the murine L-cell virus.

24. (amended) A pleiomorphic cell that is not a transgenic cell, and is derived from a eukaryotic cell, containing at least one gene evolved from the genome of said eukaryotic cell, prepared by a process according to claim 1.

25. (amended) A pleiomorphic cell that is not a transgenic cell, and is derived from a eukaryotic cell, containing at least one gene evolved from the genome of said eukaryotic cell, prepared by a process according to claim 15.

- 26. (new) A cell according to claim 24 that is a bacteria.
- 27. (new) A cell according to claim 24 that has morphology that is neither prokaryotic nor eukaryotic.

- 28. (new) A cell according to claim 25 that is a bacteria.
- 29. (new) A cell according to claim 25 that has morphology that is neither prokaryotic nor eukaryotic.